Kazia Therapeutics Ltd (KZIA) |
|
10.56 0.04 (0.38%)
|
06-18 08:42 |
|
Open: |
10.42 |
Pre. Close: |
10.52 |
|
High:
|
10.96 |
Low:
|
10.3001 |
|
Volume:
|
30,051 |
Market Cap:
|
137M |
|
|
|
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.972 - 11.016 |
11.016 - 11.053 |
|
Low:
|
10.184 - 10.236 |
10.236 - 10.28 |
|
Close:
|
10.47 - 10.555 |
10.555 - 10.628 |
|
Technical analysis |
as of: 2021-06-17 4:44:59 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 13.95 One year: 16.29 |
| Support: |
Support1: 10.12 Support2: 9.00 |
| Resistance: |
Resistance1: 11.94 Resistance2: 13.95 |
| Pivot: |
10.14 |
| Moving Average: |
MA(5): 10.56 MA(20): 9.90
MA(100): 10.63 MA(250): 8.44 |
| MACD: |
MACD(12,26): 0.11 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 53.57  %D(3): 53.72 |
| RSI: |
RSI(14): 58.74 |
| 52-week: |
High: 15.85 Low: 3.12 Change(%): 222.9 |
| Average Vol(K): |
3-Month: 8695 10-Days: 7548 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.KZIA has closed below upper band by 23.6%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 17 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 0.3800% for June 17 - Equities.com
Tue, 15 Jun 2021
Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial - Seeking Alpha
Tue, 15 Jun 2021
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma - PRNewswire
Mon, 14 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 0.4780% for June 14 - Equities.com
Thu, 10 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 2.7810% for June 10 - Equities.com
Mon, 07 Jun 2021
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient - PRNewswire
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Neutral |
Discounted cash flow: |
Neutral |
| Return on Assets: |
Neutral |
Price to Earnings: |
Neutral |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
13 |
| Shares Float (M) |
9 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
4.21 |
|
Shares Short (K)
|
41 |
|
Shares Short P. Month (K)
|
28 |
Stock Financials |
|
EPS
|
-1.060 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.510 |
|
Profit Margin
|
|
|
Operating Margin
|
-3563.68 |
|
Return on Assets (ttm)
|
-26.9 |
|
Return on Equity (ttm)
|
-59.0 |
|
Qtrly Rev. Growth
|
-99.8 |
|
Gross Profit (p.s.)
|
0.078 |
|
Sales Per Share
|
0.029 |
|
EBITDA (p.s.)
|
-0.938 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-18 |
|
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
|
PE Ratio
|
-9.96 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.21 |
|
Price to Sales
|
367.79 |
|
Price to Cash Flow
|
-7.29 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2017-07-13 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
